Scientists will be able to detect cancer earlier from blood samples after advances were made in detecting microRNA molecules using gold-plated nanoparticles.
UNSW researchers have discovered a new way to detect ultralow levels of microRNA in a blood sample which could make diagnosis of cancer and other illnesses quicker and more efficient.
The research team used nanoparticles to latch on to the targeted microRNAs (miRNAs) which enabled them to be easily extracted. One of the main benefits was that it was effective even when the miRNA was in minuscule amounts in the blood sample. Previously, a much larger sample was needed to extract similar amounts.
MicroRNAs are short RNA molecules that target some messenger RNAs (genetic material used to synthesise proteins) to prevent them from coding for a specific protein. Impaired miRNA activity has been linked with the formation of cancerous tumours as well as metastasis, the spread of cancer to other parts of the body.
Scientia Professor Justin Gooding said the nanoparticles are, in effect, dispersible electrodes. When circulated through the blood they capture the miRNA before a magnet is used to recapture the nanoparticles with the newly attached microRNA.
“Now we get more of the microRNA because the dispersible electrodes capture nearly everything in the sample,” Professor Gooding said.
“Because the capture is so effective, we get higher sensitivities and can detect much lower limits.
“And since we bring them back to the electrode under a magnet, our response time is much faster.”
One of the advantages of being quicker is that it will cost less.
“It could be orders of magnitude cheaper. Our method takes 30 minutes compared with almost 12 hours for quantitative polymerase chain reaction,” Professor Gooding said.
Key to the new technology is not just the ability to detect lower concentrations of miRNA but the ability to detect a broad range of concentrations.
“This is really important to determine whether the levels of different microRNAs have increased or decreased,” Professor Gooding said.
“We can do this very quickly compared with the gold-standard nucleic acid amplification methods. And we can do it in unprocessed blood.
“What this means is the technology has the potential to determine the levels of microRNA just from a finger prick test.”
Professor Gooding said he would expect the technology to be available within three years, pending regulatory approvals.
The new diagnostic technique follows on the heels of a similar advance made by another UNSW research team exploring cancer detection in the blood.
In that study, published in Nature Communications, a team of medical researchers led by Professor Chris Heeschen developed a new way to detect early-stage cancer tumour cells in the blood using a malaria protein. This method, which targeted individual cancer cells found in a blood sample, also used a magnet to retrieve all the targeted cancer cells.
Professor Gooding believes the two methods, while working on very different scales, would be very complementary as tools to diagnose cancer.
“The malaria protein technology works by detecting cancer cells, rare cells in particular. These are found in the blood also and so are also compatible with the liquid biopsy concept,” he said.
“We are detecting small molecules found in the blood which could also identify the type of cancer, while they are looking for rare cells that are responsible for the spread of cancer. The two technologies could work very well together.”
The Latest on: Cancer blood test
via Google News
The Latest on: Cancer blood test
- Delfi Diagnostics raises $100M for a new approach to screening blood for canceron January 13, 2021 at 6:02 am
A new method of screening the blood for the telltale signs of tumors promises to offer more chances for a successful result, and Delfi Diagnostics has raised $100 million to help make the cancer test ...
- Lung cancer symptoms: Peripheral neuropathy in your fingers or toes is a signon January 13, 2021 at 3:06 am
LUNG cancer is one of the most common and serious types of cancer - around 44,500 people are diagnosed with the condition every year in the UK. Peripheral neuropathy in your fingers or toes is a ...
- CES 2021 Jun Zhi integrated Taiwan’s top research teams to develop SAA Cancer Screening Serviceson January 12, 2021 at 11:01 pm
PRNewswire/ -- Jun Zhi, a Taiwan-based biomedical team, developed the SAA Cancer Screening Service. This service detects early-stage gastric and colorectal cancers. The service was created by ...
- Freenome’s Multiomics Blood Test Shows Promising Results in Detecting Colorectal Advanced Adenomas in a Prospective, Multi-Center Clinical Studyon January 12, 2021 at 6:00 am
Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood draw, today announced that it will be presenting ...
- JPM: Illumina inks multiple cancer diagnostic partnerships to complement upcoming Grail acquisitionon January 12, 2021 at 4:55 am
Following its $8 billion pitch last year to acquire Grail and its upcoming multi-tumor blood test, Illumina is planning a deeper dive into cancer genomics with a slew of new biopharma development ...
- GRAIL Confirms Q2 2021 Introduction of Galleri, First-of-Kind Multi-Cancer Early Detection Blood Teston January 12, 2021 at 1:52 am
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today confirmed it expects to introduce Galleri™, its multi-cancer early detection blood test, in the ...
- Healthy Living: Blood Tests Detects Cancer Recurrenceon January 11, 2021 at 2:19 pm
Some 148,000 Americans are diagnosed every year with colorectal cancer. In up to 40% of those patients, the cancer will come back after treatment. Now, a simple blood test done at home can give ...
- Grail to debut multi-cancer blood test in Q2on January 11, 2021 at 10:00 am
Grail announced today that it expects to introduce its Galleri multi-cancer early detection blood test in the second quarter of 2021.
- 25 Facts About Cancer That Could Help You Save a Lifeon January 11, 2021 at 9:23 am
The word “cancer” can be a little scary. And getting a cancer diagnosis can be, too.“Patients ask us this question all the time,” says Megan Kruse, MD, a breast oncologist with the Cleveland Clinic.
- New experimental blood test determines which pancreatic cancers will respond to treatmenton January 8, 2021 at 10:31 am
Pancreatic cancer is one of the hardest cancers to treat since the symptoms are often mild, resulting in a late-stage diagnosis, and a grim prognosis. But a new, ...
via Bing News